Patents by Inventor Qui-Lim Choo

Qui-Lim Choo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060292556
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Application
    Filed: November 9, 2005
    Publication date: December 28, 2006
    Applicant: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Patent number: 7105303
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: September 12, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 7033805
    Abstract: The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg2+ and Mn2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: April 25, 2006
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Jang Han, Joonho Choe
  • Publication number: 20050202418
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBV agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Application
    Filed: December 28, 2004
    Publication date: September 15, 2005
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20050089843
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: October 12, 2004
    Publication date: April 28, 2005
    Inventors: Robert Ralston, Frank Marcus, Kent Thudium, Barbara Gervase, John Hall, Kim Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 6861212
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: March 1, 2005
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20040091851
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: November 12, 2002
    Publication date: May 13, 2004
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20040001854
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Application
    Filed: February 18, 2003
    Publication date: January 1, 2004
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Publication number: 20030232328
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBV), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicated that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: March 14, 2003
    Publication date: December 18, 2003
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Publication number: 20030162167
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses.
    Type: Application
    Filed: July 25, 1996
    Publication date: August 28, 2003
    Inventors: MICHAEL HOUGHTON, QUI-LIM CHOO, GEORGE KUO
  • Publication number: 20030129586
    Abstract: The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg2+ and Mn2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.
    Type: Application
    Filed: November 25, 2002
    Publication date: July 10, 2003
    Inventors: Michael Houghton, Qui-Lim Choo, Jang Han, Joonho Choe
  • Publication number: 20030064499
    Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.
    Type: Application
    Filed: June 18, 2001
    Publication date: April 3, 2003
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Patent number: 6521423
    Abstract: Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: February 18, 2003
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Sergio Abrignani, David Chien, Mark Selby, Edward Glazer
  • Publication number: 20030027317
    Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteaces are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.
    Type: Application
    Filed: June 18, 2001
    Publication date: February 6, 2003
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Patent number: 6472180
    Abstract: The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Detections from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg2+ and Mn2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.
    Type: Grant
    Filed: January 15, 2000
    Date of Patent: October 29, 2002
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Jang Han, Joonho Choe
  • Publication number: 20020004048
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Application
    Filed: August 13, 2001
    Publication date: January 10, 2002
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 6312889
    Abstract: Combinations of HCV antigens that have a broader range of immunological reactivity than any single HCV antigen. The combinations consist of an antigen from the C domain of the HCV polyprotein, and at least one additional HCV antigen from either the NS3 domain, the NS4 domain, the S domain, or the NS5 domain, and are in the form of a fusion protein, a simple physical mixture, or the individual antigens commonly bound to a solid matrix.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: November 6, 2001
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Patent number: 6274148
    Abstract: Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.
    Type: Grant
    Filed: May 26, 1994
    Date of Patent: August 14, 2001
    Assignee: Chiron Corporation
    Inventors: Robert O. Ralston, Frank Marcus, Kent B. Thudium, Barbara A. Gervase, John A. Hall, Kim M. Berger, Qui-Lim Choo, Michael Houghton, George Kuo
  • Patent number: 6194140
    Abstract: The Hepatitis C Virus (HCV) NS3 protein contains amino acid motifs of a serine proteinase, a nucleotide triphosphatase (NTPase), and an RNA helicase. A carboxy fragment of the HCV NS3 protein was purified and possessed RNA helicase activity. Deletions from the amino terminus resulted in the protein becoming soluble. Deletions from the carboxy terminus do not result in a loss of helicase activity until at least 50 amino acids are deleted. The helicase activity requires ATP and divalent cations such as Mg2+ and Mn2+. The helicase activity was blocked by monoclonal antibody specific to the HCV NS3 protein.
    Type: Grant
    Filed: September 15, 1995
    Date of Patent: February 27, 2001
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, Jang Han, Joonho Choe
  • Patent number: 6171782
    Abstract: A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected with hepatitis A virus, or hepatitis B virus, and also are absent in control individuals. The HCV cDNA sequences lack substantial homology to the sequences of hepatitis delta virus (HDV) and HBV. A comparison of the sequences of amino acids encoded in the HCV cDNA with the sequences of Flaviviruses indicates that HCV may be related to the Flaviviruses. The HCV cDNA sequences and the polypeptides encoded therein are useful as reagents for the detection and therapy of HCV. The reagents provided in the invention are also useful for the isolation of NANBH agent(s), for the propagation of these agents in tissue culture, and for the screening of antiviral agents for HCV.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: January 9, 2001
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo